IGC Pharma, Inc. (IGC) income statement
IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3019% above fair value
$0.19+0.01 (+3.57%)
Close on Nov 18, 2026Market cap $20.12MP/E –Yield –
IGC Pharma, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 21.9%
- Operating margin
- -986.8%
- Net margin
- -702.1%
- Return on equity, FY2026
- –
Financial strength
- Current ratio
- 0.39
- Debt to equity
- 0.02
- Debt to assets
- 1.6%
- Cash to current liabilities
- 10.3%
Valuation
- P/E ratio
- –
- Price to sales
- 17.92
- Price to book
- 3.28
- Dividend yield
- –
See a number that looks wrong?